PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

(2021) Linde Schoenmaker et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis

(2021) Yao Jin et al.   Frontiers in Oncology

Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity

(2020) Alexandra Schnell et al.   CELL RESEARCH

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges

(2020) Kei Kunimasa et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

T‐cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment

(2020) Mei‐Chun Cai et al.   JOURNAL OF PATHOLOGY

Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle

(2020) Chenyang Li et al.   PHARMACEUTICAL RESEARCH

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

(2020) Maud Mayoux et al.   Science Translational Medicine

Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth

(2020) Sarah Davidson et al.   Cell Reports

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Mechanisms of Cancer Resistance to Immunotherapy

(2020) Rilan Bai et al.   Frontiers in Oncology

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

(2020) Qi Peng et al.   Nature Communications

Resident Memory T Cells and Their Effect on Cancer

(2020) Daniel J. Craig et al.   Vaccines

Roles of IFN-γ in tumor progression and regression: a review

(2020) Dragica Jorgovanovic et al.   Biomarker Research

CD44 as a tumor biomarker and therapeutic target

(2020) Hanxiao Xu et al.   Experimental Hematology & Oncology

Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study

(2019) Erika J Crosby et al.   CLINICAL CANCER RESEARCH

Hyaluronic Acid-Based Activatable Nanomaterials for Stimuli-Responsive Imaging and Therapeutics: Beyond CD44-Mediated Drug Delivery

(2019) Ki Young Choi et al.   ADVANCED MATERIALS

siRNA therapeutics: a clinical reality

(2019) Phei Er Saw et al.   Science China-Life Sciences

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Tumor neoantigens: from basic research to clinical applications

(2019) Tao Jiang et al.   Journal of Hematology & Oncology

Neoantigen vaccine: an emerging tumor immunotherapy

(2019) Miao Peng et al.   Molecular Cancer

CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers

(2019) Tim Kong et al.   CANCER RESEARCH

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

(2018) Xuexiang Du et al.   CELL RESEARCH

The biology and role of CD44 in cancer progression: therapeutic implications

(2018) Chen Chen et al.   Journal of Hematology & Oncology

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

Current Concepts of Antigen Cross-Presentation

(2018) Maria Embgenbroich et al.   Frontiers in Immunology

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

(2018) Antoni Ribas et al.   CELL

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Lineage tracking reveals dynamic relationships of T cells in colorectal cancer

(2018) Lei Zhang et al.   NATURE

The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab

(2017) Julia K. Tietze et al.   EUROPEAN JOURNAL OF CANCER

Polyethylenimine-based micro/nanoparticles as vaccine adjuvants [Corrigendum]

(2017) Chen Shen et al.   International Journal of Nanomedicine

A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy

(2017) Jung Min Shin et al.   JOURNAL OF CONTROLLED RELEASE

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

(2017) Janet Lau et al.   Nature Communications

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

(2017) Zuqiang Liu et al.   Nature Communications

Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma

(2017) Spyros Darmanis et al.   Cell Reports

Correction: CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion

(2017) Masanori Isogawa et al.   PLoS Pathogens

GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory

(2017) Nick M. Durham et al.   Journal for ImmunoTherapy of Cancer

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

(2016) Jung Soo Suk et al.   ADVANCED DRUG DELIVERY REVIEWS

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

(2016) Y. Lee et al.   CLINICAL CANCER RESEARCH

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy

(2016) Anish Babu et al.   IEEE TRANSACTIONS ON NANOBIOSCIENCE

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice

(2015) Anniek B. van der Waart et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo

(2015) Roun Heo et al.   CHEMICAL COMMUNICATIONS

A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo

(2015) Young-Ho Lee et al.   JOURNAL OF CONTROLLED RELEASE

Increased expression of surface CD44 in hypoxia-DCs skews helper T cells toward a Th2 polarization

(2015) Meixiang Yang et al.   Scientific Reports

B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation

(2014) Rachel M. Gibbons et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8+ T Cell-mediated Hepatic Antiviral Immunity

(2013) Joseph S Dolina et al.   Molecular Therapy-Nucleic Acids

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles

(2007) Shyh-Dar Li et al.   MOLECULAR THERAPY